Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 8, 1998 - Issue 11
Submit an article Journal homepage
22
Views
1
CrossRef citations to date
0
Altmetric
Review

Modulation of the activity of transforming growth factor beta

Ronald H Jackson Cambridge Antibody Technology Ltd., The Science Park, Melbourn, Royston, Cambridgeshire, SG8 6JJ, UK
Pages 1479-1486 | Published online: 25 Feb 2005

Bibliography

  • ROBERTS AB, ANZANO MA, LAMB LC, SMITH JM, SPORNMB: New class of transforming growth factors potenti-ated by epidermal growth factor. Proc. Natl. Acad. Sci. USA (1981) 78:5339–5343.
  • SCHLUNEGGER M, GRUTTER MG: An unusual feature re-vealed by the crystal structure at 2.2A resolution of hu-man transforming growth factor-132. Nature (1992) 358:430–434.
  • GRIFFITH DL, KECK PC, SAMPATH TK, RUEGER DC, CARL-SON WD: Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily. Proc. Natl. Acad. Sci. USA (1996) 93:878–883.
  • QIAN WS, BURMESTER J, TSANG ML et al.: Binding affin-ity of transforming growth factor-0 for its Type II re-ceptor is determined by the C-terminal region of the molecule. J. Biol. Chem. (1996) 271:30656–30662.
  • •Defines regions of the TGF-6 molecule important for recep-tor binding and therefore for targeting antagonists.
  • PADGETT RW, DAS P, KRISHNA S: TGF-13 signalling, Smads and tumor suppressors. BioEssays (1998) 20:382–391.
  • •Useful up-to-date review of TGF-6 signalling pathways.
  • ROBERTS AB, SPORN MB: The transforming growth fac-tors-13. In: Handbook of Experimental Pharmacology. Sporn MB, Roberts AB (Eds.), Springer, Heidelberg (1990):419–472.
  • MASSAGUE J: The transforming growth factor-13 family. Ann. Rev. Cell Biol. (1990) 6:597–646.
  • SHAH M, FOREMAN DH, FERGUSON MWJ: Neutralisation of TGF-131 and TGF-132 or exogenous addition of TGF-03 to cutaneous rat wounds reduces scarring. J. Cell Sci. (1995) 108:985–1002.
  • MURATA H, ZHOU L, OCHOA S, HASAN A. BADIAVAS E, FALANGA V: TGF-03 stimulates and regulates collagen synthesis through TGF-01-dependent and independ-ent mechanisms. J. Invest. Dermatol. (1997) 108:258–262.
  • O'KANE S, FERGUSON MW: Transforming growth factorOs and wound healing. Int. J. Biochem. Cell Biol. (1997) 29:63–78.
  • BORDER WA, OKUDA S, LANGUINO LR, SPORN MB, RUO-SLAHTI E: Suppression of experimental glomeru-lonephritis by antiserum against transforming growth factor 01. Nature (1990) 346:371–374.
  • LOGAN A, BERRY M, GONZALEZ AM, FRAUTSCHY SA, SPORN MB, BAIRD A: Effects of transforming growth factor 01 on scar formation in the injured central nerv-ous system of the rat. Eur. j Neurosci. (1994) 6:355–363.
  • SHAH M, FOREMAN DM, FERGUSON MWJ: Neutralising antibody to TGF-01,2 reduces cutaneous scarring in ro-dents. J. Cell. Sci. (1994) 107:1137–1157.
  • GIRT SN, HYDE DM, HOLLINGER MA: Effect of antibody to transforming growth factor 0 on bleomycin induced accumulation of lung collagen in mice. Thorax (1993) 48:959–966.
  • BORDER WA, NOBLE NA: Targeting TGF-0 for treatment of disease. Nature Med. (1995) 1:1000–1001.
  • BORDER WA, NOBLE NA: Transforming growth factor-0 in tissue fibrosis. New Engl. J. Med. (1994) 331:1286–1292.
  • •Useful review of TGF-0 in fibrosis by pioneers in the area.
  • WAHL SM, ALLEN JB, COSTA GL, WONG, HL, DASCH JR: Reversal of acute and chronic synovial inflammation by anti-transforming growth factor-0. J. Exp. Med. (1993) 177:225–230.
  • GRAINGER DJ, KEMP PR, METCALFE JC et al.: The serumconcentration of active transforming growth factor-0 is severely depressed in advanced atherosclerosis. Na-ture Med. (1995) 1:74–79.
  • CONNOR TB, ROBERTS AB, SPORN MB et al.: Correlation of fibrosis and transforming growth factor-0 Type 2 levels in the eye. J. Clin. Invest. (1989) 83:1661–1666.
  • KOZY DW, MABERLEY AL: Closure of persistent macu-lar holes with human recombinant transforming growth factor-0 2. Can. J. Ophthalmol. (1996) 31:179–182.
  • THOMPSON JT, SJAARDA RN, GLASER BM, MURPHY RP: Increased intraocular pressure after macular hole sur-gery. Am. J. Ophthalmol (1996) 121:615–622.
  • THOMPSON JT, SMIDDY WE, WILLIAMS GA et al.: Com-parison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology (1998) 105:700–706.
  • ASHCROFT GS, DODSWORTH J, VAN BOXTEL E et al.: Es-trogen accelerates cutaneous wound healing associ-ated with an increase in TGF-01 levels. Nature Med. (1997) 3:1209–1215.
  • ISAKA Y, BREES DK, IKEGAYA K et al: Gene therapy by skeletal muscle expression of decorin prevents fi-brotic disease in rat kidney. (1996) Nature Med. 2: 418–423.
  • GROTENDORST GR: Connective tissue growth factor: amediator of TGF-0 action on fibroblasts. Cytokine Growth Factor Rev. (1997) 8:171–179.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.